ords, prior exits EFTA00292538 THANK YOU! Contacts: Paul Finnegan, MD, MBA - CEO John Jaskowiak - VP, Corporate Development E-CELTM Therapies tli-CELTM Technology Transforming Hematology and Cancer Care April 2017 via the powers of C.... Engineered Endothelial Cells ANRWIPM EFTA00292539